Publisert 11.01.2017

Additional EPO patent granted

The European Patent Office has issued an additional new patent covering Regenics AS proprietary technology. The patent was granted on November 2, 2016 as Patent Number EP 2296676. The patent expires May 7th, 2029.

 The patent will be initially validated in France, Germany, Italy, Sweden, United Kingdom, Spain, Norway, and Denmark. More countries will follow.

See also: Other EPO patent news

More info: Christian Clemm, CMO at cc@regenics.no or mobile +47 95892548

The patent number is EP Patent No. 2296676

EP Patent Application No. 09742464.2

EP Regional Phase Entry of PCT/IB2009/005836

International filing Date: 07-May-2009

Title: CELLULAR EXTRACTS

For more information contact:

Christian Clemm at cc@regenics.no or mobile +47 95892548

 

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.